Skip to content
Screener

Treace Medical Concepts, Inc. TMCI Q4 2025 Annual earnings

Reported February 27, 2026 · Before market open

Revenue$62.5MBeat by $670.3K
EPS-$0.12Beat by $0.03
Revenue estimate$61.8M
EPS estimate-$0.15

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$47.7M
EPS estimate-$0.26

Financials

Q4 2025

Income statement

See full
Revenue$62.5M-9.0%
Gross profit$50.4M-9.1%
Operating income-$5.9M-2,803%
Net income-$9.4M-1,775%
EPS (diluted)-$0.14-1,300%

Balance sheet

See full
Cash & equivalents$10.7M-5.7%
Total debt$71.9M+3.2%
Total equity$87.3M-22.6%
Total assets$190.6M-12.2%

Cash flow

See full
Operating cash flow-$8.0M-90.8%
CapEx$2.4M-22.0%
Free cash flow-$10.4M-43.2%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$156.11M-66.3%
Enterprise value$217.26M-58.4%
P/S0.7×-1.5×

Profitability

See full
Gross margin79.8%-0.6pp
Operating margin-25.5%-1.0pp
Net margin-27.7%+1.2pp
FCF margin-13.9%-4.0pp

Returns & leverage

See full
Return on equity-58.9%+28.5pp
Debt / equity0.8×+0.2×
Current ratio4.3×-0.3×

FAQ

When did Treace Medical Concepts, Inc. report Q4 2025 earnings?
Treace Medical Concepts, Inc. (TMCI) reported Q4 2025 earnings on February 27, 2026 before market open.
What were Treace Medical Concepts, Inc.'s Q4 2025 revenue and EPS?
Treace Medical Concepts, Inc. reported revenue of $62.5M and eps of $-0.12 for Q4 2025.
Did Treace Medical Concepts, Inc. beat estimates in Q4 2025?
Revenue beat the consensus estimate of $61.8M by $670.3K. EPS beat the consensus estimate of $-0.15 by $0.03.
How did Treace Medical Concepts, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 9.0% from $68.7M a year earlier and eps declined 1100.0% from $-0.01.
Where can I find Treace Medical Concepts, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-079163) and the 10-K periodic report (0001193125-26-079167) directly on SEC EDGAR. The filing index links above go to sec.gov.